-
Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains
Thursday, July 20, 2017 - 11:40am | 404Read More...Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant. On Thursday, Credit Suisse reinstated coverage of Johnson...
-
Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth
Thursday, September 8, 2016 - 1:55pm | 387Read More...JPMorgan said AbbVie Inc (NYSE: ABBV) should benefit from recent acquisitions as well as pipeline updates over the long term, despite downgrading the stock to Neutral from Overweight on valuation. "[G]iven the recent strength in shares, we believe AbbVie's profile is now better reflected at current...
-
AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating
Monday, August 8, 2016 - 1:23pm | 314Read More...David Toung and Casey Meyers, analysts at Argus Research, reaffirmed a Buy rating on AbbVie Inc (NYSE: ABBV) on Monday with an $85 price target following the company's "strong" second quarter earnings print. The analysts noted that not only were AbbVie's results driven by sales of Humira and...
-
In Barclays' View, 2016's Second Half Looks 'Noisy' For AbbVie
Monday, August 1, 2016 - 11:30am | 389Read More...AbbVie Inc (NYSE: ABBV) reported another beat and raise quarter, with the 2Q revenue and EPS beating the consensus expectations. Barclays’ Geoff Meacham maintains an Equal-Weight rating on the company, with a price target of $68. Meacham mentioned that while execution remains consistent, 2H16...
-
AbbVie Falling After Q4 Report, 2016 Guidance Affirmation
Friday, January 29, 2016 - 9:14am | 240Read More...Shares of AbbVie Inc (NYSE: ABBV) were trading lower by more than 4 percent early Friday morning after the company reported its fourth quarter results. AbbVie earned $1.13 per share in the fourth quarter on revenue of $6.36 billion. Wall Street analysts were expecting the company to earn $1.12...
-
Leerink: Pharmacyclics Is Now Worth $240
Tuesday, March 3, 2015 - 4:33pm | 252Read More...In a report published Monday, Leerink analysts Howard Liang and Gena Wang boosted their price target on Pharmacyclics, Inc. (NASDAQ: PCYC) shares from $204 to $240. The reason behind the increase is not only a merger rumor, but also "intriguing PDL1 combination data. "Preclinical data...
-
Market Wrap For January 9: All Eyes on Tomorrow's Job Report
Thursday, January 9, 2014 - 5:43pm | 2416Read More...Markets were relatively calm during Thursday's trading session as investors anticipate Friday's jobs report. The December employment report is expected to show about 200,000 payroll jobs representing a steady growth and a clear sign that labor market and economy are both strong. Related:...
